GlassScriptPhysician profile
Haider Afzal
NPI 1083621023
$7,268.72
in general payments reported to CMS, 2019-2025
53 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $438 · 2021: $420 · 2022: $407 · 2023: $433 · 2024: $5,018 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,661 · Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,661.40 |
| Food and Beverage | $1,098.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photonicare INC | $4,661.40 | 2024 | Otosight Middle Ear Scope |
| Pfizer INC. | $353.47 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $310.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $296.24 | 2021-2023 | Vraylar |
| Boston Scientific Corporation | $145.42 | 2023 | |
| Lilly USA, LLC | $135.76 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $123.29 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.11 | 2019-2020 | |
| Horizon Therapeutics Plc | $114.27 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $73.75 | 2023-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $73.07 | 2022-2023 | Nuedexta, Rexulti |
| Glaxosmithkline, LLC. | $61.93 | 2023-2024 | Arexvy, Shingrix |
| Dexcom, INC. | $56.49 | 2019-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $50.36 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.24 | 2023-2024 | Jardiance |
Show all 39 companies
14 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haider Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.